



THE CANADIAN CANCER
RESEARCH **CONFERENCE**

LA **CONFÉRENCE** CANADIENNE
SUR LA RECHERCHE SUR LE CANCER



VIRTUAL PROGRAM PROGRAMME DE LA CONFÉRENCE VIRTUELLE

November 12 - 14, 2023

Halifax, NS

12 au 14 novembre 2023

Halifax, NS

ccra-acrc.ca/conference

CONFERENCE OVERVIEW – Virtual

Sunday, November 12, 2023

12:40 pm	Welcome Remarks
2:10 pm	Plenary Session – Liquid Biopsies
3:50 pm	Break
4:10 pm	Plenary Session – AI Across the Research Spectrum
5:40 pm	Break
6:10 pm	Lightning Sessions
	Bioinformatics, Big Data, AI and Technology
	Survivorship

Monday, November 13, 2023

	Concurrent Sessions
12:40 pm	Health Equity
	Innovations in Clinical Trials
	Improving the Cancer Journey of First Nations, Inuit and Métis
2:10 pm	Break
2:40 pm	Plenary Session – Clinical Innovations in the Real World
4:10 pm	Break
	Concurrent Sessions
4:40 pm	Enhancing Palliative, End-of-Life, and Survivorship Experiences
	Adolescent and Young Adult Cancer
	Tumour Microenvironment
6:10 pm	Break
	Lightning Sessions
6:50 pm	Metastasis
	Screening, Early Detection, Diagnosis and Prognosis

Tuesday, November 14, 2023

11:40 am	Plenary Session – Environment and Cancer
	Lightning Sessions
1:10 pm	Metabolism
	Patient Experience and Advocacy
1:40 pm	Break
	Concurrent Sessions
2:10 pm	Microbiome
	Advances in Cancer Biology
	Cancer Prevention
	Advances in Cancer Treatments
3:40 pm	Closing Remarks

***Scientific Program subject to change**

The following plenary sessions will be available online via live stream: AI Across the Research Spectrum, Clinical Innovations in the Real World, and Environment and Cancer

All other sessions listed will be recorded and made available at the times listed above.

APERÇU DU PROGRAMME – Virtuel

Dimanche 12 novembre 2023

12 h 40	Mot de bienvenue
14 h 10	Séance plénière – Les biopsies liquides
15 h 50	Pause
16 h 10	Séance plénière – L'IA dans tous les domaines de la recherche
17 h 40	Pause
18 h 10	Séances éclair
	La bio-informatique, les mégadonnées, l'IA et la technologie
	La survie

Lundi 13 novembre 2023

	Séances simultanées		
12 h 40	L'équité en santé	Les innovations dans les essais cliniques	Améliorer le parcours face au cancer des Premières Nations, des Inuits et des Métis
14 h 10	Pause		
14 h 40	Séance plénière – Les innovations cliniques dans le monde réel		
16 h 10	Pause		
	Séances simultanées		
16 h 40	Améliorer les expériences des soins palliatifs, des soins de fin de vie et de la survie	Le cancer chez les adolescents et les jeunes adultes	Le micro-environnement tumoral
18 h 10	Pause		
	Séances éclair		
18 h 50	Les métastases	Le dépistage, la détection précoce, le diagnostic et le pronostic	

Mardi 14 novembre 2023

11 h 40	Séance plénière – L'environnement et le cancer		
	Séances éclair		
13 h 10	Le métabolisme	L'expérience des patients et la défense de leurs intérêts	
13 h 40	Pause		
	Séances simultanées		
14 h 10	Le microbiome	Progrès accomplis dans la biologie du cancer	Progrès accomplis dans les traitements contre le cancer
15 h 40	Mot de la fin		

* Programme sujet à changement

Les séances plénières seront accessibles en ligne par le biais d'une diffusion en continu en direct : L'IA dans tous les domaines de la recherche, Les innovations cliniques dans le monde réel, et L'environnement et le cancer.

Toutes les autres séances seront enregistrées et accessibles aux heures indiquées ci-dessus.

SUNDAY, NOVEMBER 12, 2023

12:40 pm

Welcome Remarks

2:10 pm

Plenary Session – Liquid Biopsies

Chairs:

Dr. Sherri Christian
Memorial University of Newfoundland, Beatrice Hunter Cancer Research Institute, Marathon of Hope Cancer Centres, Terry Fox Research Institute

Ms. Melissa Coombs
Patient Partner

Dr. Natasha Leighl
Princess Margaret Cancer Centre, University of Toronto

Dr. Rodney Ouellette
Atlantic Cancer Research Institute

Dr. Trevor Pugh
Princess Margaret Cancer Centre, University of Toronto

3:50 pm

Break

4:10 pm

Plenary Session – AI Across the Research Spectrum

Chairs:

Dr. Ali Bashashati
University of British Columbia, Vancouver Coastal Health Research Institute

Dr. Rosilene Kraft
Patient Partner

Dr. Manisha Bahl
Mass General Research Institute, Harvard University

Dr. John Lewis
Faculty of Medicine & Dentistry, University of Alberta

Dr. Muhammad Mamdani
Unity Health, St. Michael's Hospital, University of Toronto

5:40 pm

Break

6:10 pm

LIGHTNING SESSIONS

Bioinformatics, Big Data, AI and Technology

Developing the pan-Canadian Cancer Data Strategy (cancer data strategy) to guide cancer data improvements and implementation efforts

ARS2 Association with subnuclear Paraspeckles: Implications for Hepatocellular Carcinoma Progression and Drug Resistance

Ms. Natalie Fitzgerald
Canadian Partnership Against Cancer

Dr. Gobi Thillainadesan
Sunnybrook Research Institute

Survivorship

Missed Opportunities in Supporting Informal Cancer Caregiver (and Patient) Health

Mr. Thomas Christensen
Dalhousie University

Missed Opportunities in Supporting Informal Cancer Caregiver (and Patient) Health

Mr. Thomas Christensen
Dalhousie University

Development of a polygenic score to predict cisplatin-induced ototoxicity

Dr. Britt Drogemoller
University of Manitoba

Adjuvant Treatment in High-Grade Serous Endometrial Carcinoma: A Comprehensive Institutional Review

Dr. Sedighe Esmailzade
McGill University Health Center

Finding Intimacy Without Sex: Exploring the impact of lost intimacy and sexual function after cancer

Ms. Cecile Proctor
University of New Brunswick

PRELIMINARY

12:40 am

CONCURRENT SESSIONS

Health Equity

Chair:

Dr. David Busolo

University of New Brunswick, Faculty of Nursing, Moncton Campus, Beatrice Hunter Cancer Research Institute

Exploring primary care provider barriers and enablers to implementation of cancer screening with patients experiencing marginalization

Disparities In Clinical Trial Enrolment At A Canadian Comprehensive Cancer Centre: A Fifteen-Year Retrospective Study

Cancer incidence in people with intellectual or developmental disabilities: Two population-based retrospective cohort studies in Manitoba and Ontario, Canada

Dr. Mandana Vahabi

Toronto Metropolitan University

Dr. Arlinda Ruco

St. Francis Xavier University

Dr. Gilla Shapiro

Princess Margaret Cancer Centre

Dr. Alyson Mahar

Queen's University

Innovations in Clinical Trials

Chair:

Dr. Wendy Parulekar

Canadian Cancer Trials Group, Queen's University

Cost-Effectiveness Analysis of the Prostate Cancer Patient Empowerment Program (PC-PEP)

A phase IIb randomized placebo-controlled trial testing a long-chain omega-3 fatty acid MAG-EPA dietary supplement on prostate cancer aggressiveness

Dr. PJ Devereaux

McMaster University

Ms. Alexandra Nuyens

Dalhousie University

Dr. Karine Robitaille

CHU de Québec, Université Laval Research Center

Improving the Cancer Journey of First Nations, Inuit and Métis

2:10 pm

Break

2:40 pm

Plenary Session – Clinical Innovations in the Real World

Chairs:

Dr. Sachin Katyal

University of Manitoba, CancerCare Manitoba

Ms. Ruth Ackerman

Patient Partner

Dr. June Carroll

Faculty of Medicine, University of Toronto, Granovsky Gluskin Family Medicine Centre, Sinai Health

Dr. Tony Reiman

Atlantic Cancer Research Institute, Beatrice Hunter Cancer Research Institute, Dalhousie University, University of New Brunswick

Dr. Sheila Singh

Cancer Research Centre, McMaster University

4:10 pm

Break

CONCURRENT SESSIONS

Enhancing Palliative, End-of-Life, and Survivorship Experiences

Chair:

Dr. Harvey Chochinov
University of Manitoba

Dr. Harvey Chochinov
University of Manitoba

Dr. Mathieos Beylani
University of British Columbia

Adolescent and Young Adult Cancer

Chair:

Dr. Uri Tabori
The Hospital for Sick Children

Sponsored by:



Dr. Uri Tabori
The Hospital for Sick Children

Developing a machine learning classifier for the diagnosis of Li-Fraumeni Syndrome

Ms. Brianne Laverty
The Hospital for Sick Children

Tumour Microenvironment

Chair:

Dr. J. Patrick Murphy
Department of Biology, University of Prince Edward Island, Department of Pathology, University of Prince Edward Island, Beatrice Hunter Cancer Research Institute

Prognosis and chemoresistance in ovarian cancer: the role of immune marker expression

Dr. Arvind Mer
University of Ottawa

6:10 pm

Break

6:50 pm

LIGHTNING SESSIONS

Metastasis

Investigation of roles of DNA methylation inhibition and STING agonist in the treatment of metastatic triple-negative breast cancer

Dr. Sofiane Berrazouane
Lady Davis Institute, McGill University

Exploring a link among protein synthesis, mitochondrial dysfunction, and epithelial-to-mesenchymal transition

Dr. Stephen Lewis
Atlantic Cancer Research Institute

Counterbalance between Wnt/ β -catenin and ATF2-dependent signalling pathways drives cancer cell invasion and intravasation

Dr. Konstantin Stoletov
University of Alberta

Screening, Early Detection, Diagnosis and Prognosis

DNA Organization Measurements from All the Individual Cells Within Tissue can be Highly Predictive of Cancer Cell Aggressiveness

Dr. Calum MacAulay
BC Cancer

Is Canada prepared for Primary HPV-testing in Cervical Cancer Screening? A national study of the Knowledge, Attitudes, and Beliefs of Under and Adequately Screened Canadians

Dr. Samara Perez
McGill University Health Center

Making Progress in Cancer Control: The Number of Cancer Deaths Avoided in Canada

Dr. Matt Warkentin
University of Calgary

TUESDAY, NOVEMBER 14, 2023

11:40 am

Plenary Session – Environment and Cancer
Chairs:

Dr. Robin Urquhart
Dalhousie University, Atlantic Partnership for Tomorrow's Health, Beatrice Hunter Cancer Research Institute, Nova Scotia Health Authority

Dr. Don Desserud
Patient Partner

Dr. Aaron Goodarzi
Cumming School of Medicine, University of Calgary

Dr. Fiona Miller
Centre for Sustainable Health Systems, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto

Ms. Carol Crowe
Creative Fire

1:10 pm

LIGHTNING SESSIONS

Metabolism

XPO1/CRM1 inhibition modulates autophagy and protein metabolism in cancer cells	Miss Aziliz Duverger <i>Université de Moncton</i>
Delineating and targeting a novel metabolism-based post-translational mechanism regulating the abundance of the 'undruggable' oncoprotein c-MYC in medulloblastoma	Emma Martell <i>University of Manitoba</i>
The secret life of a Krebs Cycle enzyme in aggressive cancers and optic neuropathies	Dr. Michael Moran <i>Hospital for Sick Children, University of Toronto</i>

Patient Experience and Advocacy

Mental Health Among People Living With and Beyond Colorectal Cancer: A Patient-Oriented Constructivist Grounded Theory	Dr. Vicki Cheng <i>University of British Columbia</i>
The Rethinking Clinical Trials (REaCT) program: transforming pragmatic, practice-changing, patient-centred research across Canada	Dr. Mark Clemons <i>The Ottawa Hospital Research Institute</i>
Ethical issues experienced in relationships between patients and other team members developing a strategy for meaningful patient engagement in cancer research funding	Dr. Jenny Leese <i>University of Ottawa</i>
Co-creation of a patient engagement strategy in cancer research funding	Ms. Suzanne Bays <i>Canadian Cancer Society</i>
	Mr. Donald Wood <i>Canadian Cancer Society</i>

1:40 pm

Break

2:10 pm

CONCURRENT SESSIONS

Microbiome

Chair:

Dr. Betrand Routy
CHUM / CRCHUM

Dr. Betrand Routy
CHUM / CRCHUM

Dr. Robyn Wright
Dalhousie University

Advances in Cancer Biology

Chair:

Dr. Paola Marcato

Department of Pathology, Dalhousie University

Genome-Wide CRISPR Cas9 Screen Reveals a PARG - PTEN - Dependent Vulnerability in Melanoma

Mr. Emmanuel Asante

McGill University

Improving the cancer survivorship narrative by implanting artificial Intelligence along the health care continuum

Dr. Paola Marignani

Dalhousie University

Cancer Prevention

Chair:

Dr. Rachel Murphy

BC Cancer Research Centre, University of British Columbia

Exploring the Etiology of Rare Cancers Using a Large Occupational Cohort

Dr. Rachel Murphy

BC Cancer Research Centre, University of British Columbia

The effectiveness and cost-effectiveness of population-level policies to reduce alcohol use: a systematic umbrella review

Dr. Paul Demers

Occupational Cancer Research Centre, Ontario Health

Ms. Umaima Abbas

University of Western Ontario

Advances in Cancer Treatments

Chair:

Dr. Sachin Katyal

University of Manitoba, CancerCare Manitoba

EZH2 inhibition circumvents PRAME-mediated retinoid resistance in keratinocyte carcinomas

Mr. Brandon Ramchatesingh

McGill University

3:40 pm

Closing Remarks

***Scientific Program subject to change**